NCT03046251: A reported trial by State University of New York at Buffalo
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03046251 |
|---|---|
| Title | Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 31, 2015 |
| Completion date | Dec. 31, 2023 |
| Required reporting date | Dec. 30, 2024, midnight |
| Actual reporting date | Sept. 13, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |